Christopher A. Herr
Senior Managing Director @ Oxford Finance LLC
Christopher A. Herr is a post-ipo debt investor at Oxford Finance LLC focused on Biotechnology and Health Care. Christopher A. Herr is the Senior Managing Director at Oxford Finance LLC. He was a former Executive Vice President at Coghill Capital Management.Mr. Herr has been a member of Oxford’s business development team since 2002. He is responsible for business development for life sciences and healthcare services companies worldwide. Before joiningOxford, Mr. Herr established the Southwest operations for Charter Financial, which provided debt capital to venture-backed, life sciences companies. Previously, he had been co-founder and executive vice president of Coghill Capital Management. He has taught numerous public seminars as well as lectured at Penn State University on the topics of equity investing, portfolio management, and estate planning. He is currently a board member of several privately held companies. Mr. Herr holds a B.A. in Liberal Arts from Pennsylvania State University and an M.B.A. from the London Business School.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 73%
Last updated:
For AI agents: llms.txt
Industries Christopher A. Herr invests in
Stages Christopher A. Herr invests in
Countries Christopher A. Herr invests in
Investment Focus
Industry
- Biotechnology 19 (86%)
- Health Care 13 (59%)
- Therapeutics 9 (41%)
- Medical 8 (36%)
- Medical Device 6 (27%)
Stage
- Post-IPO Debt 11 (50%)
- Debt Financing 9 (41%)
- Post-IPO Equity 1 (5%)
Country
- United States 17 (77%)
- Germany 1 (5%)
- Ireland 1 (5%)
- Switzerland 1 (5%)
- United Kingdom 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ALX Oncology
|
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University.This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1. | $100M / Post-IPO Debt / Oct 31, 2022 | |
Antheia
|
Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering —reconstructing complex molecules in yeast to bring to market next-generation plant-inspired medicines. | $40M / Debt Financing / Jun 22, 2022 | |
SeLux Diagnostics
|
SeLux Diagnostics is a developer of the Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients. The company was founded in 2014 and is based in Charlestown, MA. | $30M / Debt Financing / Jun 01, 2022 | |
Centogene
|
CENTOGENE is one of the largest genetic biotech companies worldwide, the European market leader, and one of the global leaders in genetic diagnostic analyses of rare inherited diseases. Transforming global genetic data into medical decisions, that are focused on creating broarder awareness for patients of all ethnicities around the world. CENTOGENEis a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for Patients. With headquarters in Rostock, Germany and further operations in Berlin, Germany as well as Cambridge, Massachusetts, USA, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families. CENTOGENE provides the full spectrum of modern methods and technology for human genetics analysis; it is active in research and is constantly developing new and innovative products for human genetics. | $45M / Post-IPO Debt / Feb 01, 2022 | |
Kezar Life Sciences
|
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergiesbetween protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. | $50M / Post-IPO Debt / Nov 10, 2021 | |
Viracta Therapeutics
|
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application ofthis inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. | $50M / Post-IPO Debt / Nov 05, 2021 | |
4D Pharma
|
4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novelbacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D currently has a pipeline of 15 therapeutic programmes covering autoimmune diseases, CNS disorders and cancer; with two programmes in patient trials, and the expectation to initiate another three programmes over the coming twelve months. | $29.9M / Post-IPO Debt / Jul 29, 2021 | |
KALA BIO
|
Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines. | $125M / Post-IPO Debt / May 12, 2021 | |
Mainstay Medical
|
Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $50M / Debt Financing / Apr 20, 2021 | |
RxSight
|
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens(IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. | $60M / Debt Financing / Dec 01, 2020 | |
| See all 22 investments → | |||
Co-Investors
About Oxford Finance LLC
Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide. Their capital provides clients with the fuel needed for innovation and growth.
Oxford Finance LLC Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam K. Soller
Managing Director
|
|||
|
Christopher A. Herr
Senior Managing Director
|
|||
Colette Hastings Featherly
Vice President, Corporate Finance
|
|||
Darren J. Margulis
Senior Director, Credit & Portfolio Management
|
|||
J. Alden Philbrick
President & Chief Executive Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christopher A. Herr invest in?
Christopher A. Herr invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Debt and Debt Financing stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Christopher A. Herr last invest?
The most recent investment recorded for Christopher A. Herr closed in Oct 2022. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
